NEW YORK (AP) ? Shares of Acadia Pharmaceuticals Inc. more than doubled to their highest price in more than three years Tuesday after the company said its drug pimavanserin reduced psychosis in patients with Parkinson's disease. The company said anti-psychotic drugs are sometimes used to treat the condition, but those drugs can increase the risk of death as well as side effects like the loss of motor control. The company is also running midstage trials of the drug as a treatment for schizophrenia and for psychosis in Alzheimer's disease.
No comments:
Post a Comment